Tango Therapeutics (TNGX) Current Deferred Revenue (2020 - 2025)
Tango Therapeutics (TNGX) posted quarterly Current Deferred Revenue of $23.4 million for Q2 2025, down 1.24% year-over-year from $23.7 million in Q2 2024, and up 19.99% quarter-over-quarter from $19.5 million in Q1 2025.
Tango Therapeutics (TNGX) Current Deferred Revenue (2020 - 2025) Analysis & Trends
Tango Therapeutics' Current Deferred Revenue history runs 6 years deep, the most recent figure standing at $23.4 million for Q2 2025.
- In Q2 2025, Current Deferred Revenue fell 1.24% year-over-year to $23.4 million; the TTM figure through Jun 2025 stood at $23.4 million (down 1.24% YoY), while the FY2024 annual figure was $17.6 million, down 31.37% from the prior year.
- Current Deferred Revenue for Q2 2025 stood at $23.4 million, up from $19.5 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $34.0 million in Q1 2023, with the low at $15.6 million in Q3 2024.
- The 5-year median for Current Deferred Revenue is $25.8 million (2021), against an average of $25.7 million.
- The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue surged 35.91% in 2023, then sank 42.37% in 2024.
- Tango Therapeutics' Current Deferred Revenue stood at $26.0 million in 2021, then rose by 22.17% to $31.8 million in 2022, then retreated by 19.26% to $25.7 million in 2023, then sank by 31.37% to $17.6 million in 2024, then soared by 32.67% to $23.4 million in 2025.
- Business Quant data shows TNGX's Current Deferred Revenue at $23.4 million in Q2 2025, $19.5 million in Q1 2025, and $17.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Tango Therapeutics | 4.32 Bn | 3.30 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 23.37 Mn |
| Mar 31, 2025 | 19.48 Mn |
| Dec 31, 2024 | 17.62 Mn |
| Sep 30, 2024 | 15.60 Mn |
| Jun 30, 2024 | 23.67 Mn |
| Mar 31, 2024 | 23.07 Mn |
| Dec 31, 2023 | 25.67 Mn |
| Sep 30, 2023 | 27.07 Mn |
| Jun 30, 2023 | 33.85 Mn |
| Mar 31, 2023 | 34.01 Mn |
| Dec 31, 2022 | 31.79 Mn |
| Sep 30, 2022 | 28.48 Mn |
| Jun 30, 2022 | 28.20 Mn |
| Mar 31, 2022 | 25.02 Mn |
| Dec 31, 2021 | 26.02 Mn |
| Sep 30, 2021 | 27.81 Mn |
| Dec 31, 2020 | 31.98 Mn |